CC
SION

Casdin Capital’s Sionna Therapeutics SION Stock Holding History

Casdin Capital’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.6M Buy
+400,000
New +$16M 0.88% 23

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Casdin Capital's SION Position: Q2 2026 in Review

Casdin Capital opened a new position in Sionna Therapeutics (SION) in Q2 2026: 400,000 shares worth $17.6M. The stake represents 0.88% of the portfolio and ranks #23 among its holdings.

147 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • Casdin Capital held 400,000 shares of Sionna Therapeutics worth $17.6M as of Q2 2026.
  • Sionna Therapeutics was a new Casdin Capital position in Q2 2026.
  • Sionna Therapeutics made up 0.88% of Casdin Capital's portfolio in Q2 2026, its #23 holding.
  • 147 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.